Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

The predictive value of sentinel node biopsy in early breast cancer after neo-adjuvant chemotherapy: A prospective study.

Najim O, Dockx Y, Huyghe I, van den Wyngaert T, Papadimitriou K, Tjalma WAA, Huizing MT.

Eur J Obstet Gynecol Reprod Biol. 2018 Oct;229:108-111. doi: 10.1016/j.ejogrb.2018.06.040. Epub 2018 Jun 28.

PMID:
30145524
2.

Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit.

Tjalma WAA, Van den Mooter T, Mertens T, Bastiaens V, Huizing MT, Papadimitriou K.

Eur J Obstet Gynecol Reprod Biol. 2018 Feb;221:46-51. doi: 10.1016/j.ejogrb.2017.12.006. Epub 2017 Dec 7.

PMID:
29245056
3.

The exploding tumour on breast magnetic resonance imaging: an infected skin comedo.

Tjalma W, Huizing MT.

Ann R Coll Surg Engl. 2017 Nov;99(8):e221-e222. doi: 10.1308/rcsann.2017.0130. Epub 2017 Sep 15.

4.
5.

A clitoral verrucous carcinoma in an area of lichen planus has aggressive features.

Tjalma WA, Siozopoulou V, Huizing MT.

World J Surg Oncol. 2017 Jan 6;15(1):7. doi: 10.1186/s12957-016-1069-0.

6.

Neoadjuvant systemic therapy in breast cancer: Challenges and uncertainties.

Van de Wiel M, Dockx Y, Van den Wyngaert T, Stroobants S, Tjalma WAA, Huizing MT.

Eur J Obstet Gynecol Reprod Biol. 2017 Mar;210:144-156. doi: 10.1016/j.ejogrb.2016.12.014. Epub 2016 Dec 14. Review.

PMID:
28039758
7.

The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives.

Papadmitriou K, Trinh XB, Altintas S, Van Dam PA, Huizing MT, Tjalma WA.

Facts Views Vis Obgyn. 2015;7(3):176-80.

8.

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.

Awada A, Garcia AA, Chan S, Jerusalem GH, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ, Cocquyt V, Sideras K, Young DE, Zhao C, Chia YL, Hoch U, Hannah AL, Perez EA; NKTR-102 Study Group.

Lancet Oncol. 2013 Nov;14(12):1216-25. doi: 10.1016/S1470-2045(13)70429-7. Epub 2013 Oct 4.

PMID:
24095299
9.
10.

Fine tuning of the Van Nuys prognostic index (VNPI) 2003 by integrating the genomic grade index (GGI): new tools for ductal carcinoma in situ (DCIS).

Altintas S, Toussaint J, Durbecq V, Lambein K, Huizing MT, Larsimont D, Van Marck E, Vermorken JB, Tjalma WA, Sotiriou C.

Breast J. 2011 Jul-Aug;17(4):343-51. doi: 10.1111/j.1524-4741.2011.01091.x. Epub 2011 Jun 6.

PMID:
21645166
11.

RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?

Van den Wyngaert T, Wouters K, Huizing MT, Vermorken JB.

Support Care Cancer. 2011 Dec;19(12):2035-40. doi: 10.1007/s00520-010-1061-0. Epub 2011 Jan 4.

PMID:
21203781
12.

Prognostic value of bone scintigraphy in cancer patients with osteonecrosis of the jaw.

Van den Wyngaert T, Huizing MT, Fossion E, Vermorken JB.

Clin Nucl Med. 2011 Jan;36(1):17-20. doi: 10.1097/RLU.0b013e3181feeb72.

PMID:
21157201
13.

Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Specenier P, Rasschaert M, Vroman P, Van den Brande J, Dyck J, Schrijvers D, Huizing MT, Vermorken JB.

Am J Clin Oncol. 2011 Oct;34(5):472-7. doi: 10.1097/COC.0b013e3181ec5f16.

PMID:
20938321
14.

Scintigraphic evaluation of mandibular bone turnover in patients with solid tumors receiving zoledronic acid.

Van den Wyngaert T, Huizing MT, Fossion E, Vermorken JB.

Oral Oncol. 2010 Mar;46(3):214-8. doi: 10.1016/j.oraloncology.2010.01.001. Epub 2010 Feb 6.

PMID:
20138570
15.

Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.

Specenier P, Rasschaert M, Van den Brande J, Dyck J, Schrijvers D, Huizing MT, Vermorken JB.

Anticancer Drugs. 2010 Mar;21(3):306-12. doi: 10.1097/CAD.0b013e3283349994.

PMID:
20087171
16.

Docetaxel, ifosfamide and cisplatin (DIP) in squamous cell carcinoma of the head and neck.

Specenier PM, Van Den Brande J, Schrijvers D, Huizing MT, Altintas S, Dyck J, Van Den Weyngaert D, Van Laer C, Vermorken JB.

Anticancer Res. 2009 Dec;29(12):5137-42.

17.

A non-randomized comparison of gemcitabine-based chemoradiation with or without induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck.

Specenier PM, Weyler J, Van Laer C, Van den Weyngaert D, Van den Brande J, Huizing MT, Altintas S, Vermorken JB.

BMC Cancer. 2009 Aug 6;9:273. doi: 10.1186/1471-2407-9-273.

18.

Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.

Altintas S, Lambein K, Huizing MT, Braems G, Asjoe FT, Hellemans H, Van Marck E, Weyler J, Praet M, Van den Broecke R, Vermorken JB, Tjalma WA.

Breast J. 2009 Mar-Apr;15(2):120-32. doi: 10.1111/j.1524-4741.2009.00686.x.

PMID:
19292797
19.

Bisphosphonates in oncology: rising stars or fallen heroes.

Van den Wyngaert T, Huizing MT, Fossion E, Vermorken JB.

Oncologist. 2009 Feb;14(2):181-91. doi: 10.1634/theoncologist.2008-0209. Epub 2009 Jan 29. Review.

20.

Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome.

Van den Wyngaert T, Claeys T, Huizing MT, Vermorken JB, Fossion E.

Ann Oncol. 2009 Feb;20(2):331-6. doi: 10.1093/annonc/mdn630. Epub 2008 Oct 26.

PMID:
18953067
21.

Disambiguating the bisphosphonates.

Van den Wyngaert T, Huizing MT, Vermorken JB.

Ann Oncol. 2008 Jul;19(7):1357-9. doi: 10.1093/annonc/mdn356. Epub 2008 Jun 2. No abstract available.

PMID:
18522931
22.

Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens.

Nannan Panday VR, van Warmerdam LJ, Huizing MT, Ten Bokkel Huinink WW, Vermorken JB, Giaccone G, Veenhof CH, Schellens JH, Beijnen JH.

Clin Drug Investig. 1998;15(4):327-35.

PMID:
18370488
23.

Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study.

Joerger M, Huitema AD, Huizing MT, Willemse PH, de Graeff A, Rosing H, Schellens JH, Beijnen JH, Vermorken JB.

Br J Clin Pharmacol. 2007 Nov;64(5):622-33.

24.

Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemonaive patients with squamous cell carcinoma of the head and neck: long-term follow up data.

Specenier PM, Van den Weyngaert D, Van Laer C, Weyler J, Van den Brande J, Huizing MT, Dyck J, Schrijvers D, Vermorken JB.

Ann Oncol. 2007 Nov;18(11):1856-60. Epub 2007 Sep 6.

PMID:
17823386
25.

The value of the Van Nuys Prognostic Index in ductal carcinoma in situ of the breast: a retrospective analysis.

Asjoe FT, Altintas S, Huizing MT, Colpaert C, Marck EV, Vermorken JB, Tjalma WA.

Breast J. 2007 Jul-Aug;13(4):359-67.

PMID:
17593040
26.

Osteonecrosis of the jaw related to the use of bisphosphonates.

Van den Wyngaert T, Huizing MT, Vermorken JB.

Curr Opin Oncol. 2007 Jul;19(4):315-22. Review.

PMID:
17545793
27.

Small-cell carcinoma of the penile urethra: a case report and a short review of the literature.

Altintas S, Blockx N, Huizing MT, Van den Brande J, Hoekx L, Bogers JP, Van Marck E, Vermorken JB.

Ann Oncol. 2007 Apr;18(4):801-4. Epub 2006 Dec 20. No abstract available.

PMID:
17182974
28.

Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?

Van den Wyngaert T, Huizing MT, Vermorken JB.

Ann Oncol. 2006 Aug;17(8):1197-204. Review.

PMID:
16873439
29.

Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients.

Meerum Terwogt J, van Tellingen O, Nannan Panday VR, Huizing MT, Schellens JH, ten Bokkel Huinink WW, Boschma MU, Giaccone G, Veenhof CH, Beijnen JH.

Anticancer Drugs. 2000 Oct;11(9):687-94.

PMID:
11129729
30.

Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion.

Rosing H, Lustig V, van Warmerdam LJ, Huizing MT, ten Bokkel Huinink WW, Schellens JH, Rodenhuis S, Bult A, Beijnen JH.

Cancer Chemother Pharmacol. 2000;45(3):213-8.

PMID:
10663639
31.

A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel.

Nannan Panday VR, van Warmerdam LJ, Huizing MT, Ten Bokkel Huinink WW, Schellens JH, Beijnen JH.

J Cancer Res Clin Oncol. 1999 Nov;125(11):615-20.

PMID:
10541968
32.

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.

van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH.

Br J Cancer. 1999 Sep;81(2):330-5.

33.

A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen.

Panday VR, van Warmerdam LJ, Huizing MT, Rodenhuis S, Schellens JH, Beijnen JH.

Cancer Chemother Pharmacol. 1999;43(5):435-8.

PMID:
10100601
34.

Pharmacologic study of 3-hour 135 mg M-2 paclitaxel in platinum pretreated patients with advanced ovarian cancer.

Panday VR, Huizing MT, van Warmerdam LJ, Dubbelman RC, Mandjes I, Schellens JH, Huinink WW, Beijnen JH.

Pharmacol Res. 1998 Sep;38(3):231-6.

PMID:
9782075
35.
36.

Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function.

Panday VR, Huizing MT, Willemse PH, De Graeff A, ten Bokkel Huinink WW, Vermorken JB, Beijnen JH.

Semin Oncol. 1997 Aug;24(4 Suppl 11):S11-34-S11-38. Review.

PMID:
9314297
37.

Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.

Huizing MT, van Warmerdam LJ, Rosing H, Schaefers MC, Lai A, Helmerhorst TJ, Veenhof CH, Birkhofer MJ, Rodenhuis S, Beijnen JH, ten Bokkel Huinink WW.

J Clin Oncol. 1997 May;15(5):1953-64.

PMID:
9164207
38.

Clinical pharmacology of carboplatin administered in combination with paclitaxel.

van Warmerdam LJ, Huizing MT, Giaccone G, Postmus PE, ten Bokkel Huinink WW, van Zandwijk N, Koolen MG, Helmerhorst TJ, van der Vijgh WJ, Veenhof CH, Beijnen JH.

Semin Oncol. 1997 Feb;24(1 Suppl 2):S2-97-S2-104.

PMID:
9045347
39.

Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.

Huizing MT, Giaccone G, van Warmerdam LJ, Rosing H, Bakker PJ, Vermorken JB, Postmus PE, van Zandwijk N, Koolen MG, ten Bokkel Huinink WW, van der Vijgh WJ, Bierhorst FJ, Lai A, Dalesio O, Pinedo HM, Veenhof CH, Beijnen JH.

J Clin Oncol. 1997 Jan;15(1):317-29.

PMID:
8996159
40.

Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography.

Sparreboom A, van Tellingen O, Huizing MT, Nooijen WJ, Beijnen JH.

J Chromatogr B Biomed Appl. 1996 Jun 7;681(2):355-62.

PMID:
8811447
41.

Isolation, purification and biological activity of major docetaxel metabolites from human feces.

Sparreboom A, Van Tellingen O, Scherrenburg EJ, Boesen JJ, Huizing MT, Nooijen WJ, Versluis C, Beijnen JH.

Drug Metab Dispos. 1996 Jun;24(6):655-8.

PMID:
8781781
42.

Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography.

Huizing MT, Sparreboom A, Rosing H, van Tellingen O, Pinedo HM, Beijnen JH.

J Chromatogr B Biomed Appl. 1995 Dec 15;674(2):261-8.

PMID:
8788155
43.

Intermittent continuous infusion of ifosfamide and 5-fluorouracil in patients with advanced adenocarcinoma of the pancreas.

Poorter RL, Bakker PJ, Huizing MT, Taat CW, Rietbroek RC, Gouma DJ, Rauws EA, Veenhof CH.

Ann Oncol. 1995 Dec;6(10):1048-9.

PMID:
8750159
44.
45.

Photodynamic therapy in AIDS-related cutaneous Kaposi's sarcoma.

Hebeda KM, Huizing MT, Brouwer PA, van der Meulen FW, Hulsebosch HJ, Reiss P, Oosting J, Veenhof CH, Bakker PJ.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Sep 1;10(1):61-70.

PMID:
7648286
46.

High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.

Vermorken JB, ten Bokkel Huinink WW, Mandjes IA, Postma TJ, Huizing MT, Heimans JJ, Beijnen JH, Bierhorst F, Winograd B, Pinedo HM.

Semin Oncol. 1995 Aug;22(4 Suppl 8):16-22.

PMID:
7543699
47.

High-performance liquid chromatographic procedures for the quantitative determination of paclitaxel (Taxol) in human urine.

Huizing MT, Rosing H, Koopman F, Keung AC, Pinedo HM, Beijnen JH.

J Chromatogr B Biomed Appl. 1995 Feb 17;664(2):373-82.

PMID:
7780590
48.

Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces.

Sparreboom A, Huizing MT, Boesen JJ, Nooijen WJ, van Tellingen O, Beijnen JH.

Cancer Chemother Pharmacol. 1995;36(4):299-304.

PMID:
7628049
49.

Taxanes: a new class of antitumor agents.

Huizing MT, Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CH, Vermorken JB, Pinedo HM, Beijnen JH.

Cancer Invest. 1995;13(4):381-404. Review.

PMID:
7627725
50.

Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol).

Beijnen JH, Huizing MT, ten Bokkel Huinink WW, Veenhof CH, Vermorken JB, Giaccone G, Pinedo HM.

Semin Oncol. 1994 Oct;21(5 Suppl 8):53-62. Review.

PMID:
7939764

Supplemental Content

Loading ...
Support Center